What's new? Log in Free sign up

Verrica Pharmaceuticals (VRCA)

Company Profile

Company profile

Ticker

VRCA

Exchange

Website

www.verrica.com

CEO

Jayson M. Rieger

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • AbbVie • Teva Pharmaceutical Industries Limited • Bausch Health Companies • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris ...

Former names

New Newscorp Inc, New Newscorp LLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

VRCA stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Verrica Pharmaceuticals Announces Private Placement Financing of $50

Quarterly report

14 Nov 25

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

Quarterly report

12 Aug 25

Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Material Modifications to Rights of Security Holders

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Submission of Matters to a Vote of Security Holders

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Verrica Pharmaceuticals Inc.

Beneficial ownership report (amended)

Noah L. Rosenberg

Verrica Pharmaceuticals Inc.

Beneficial ownership report (amended)

Beneficial ownership report (amended)

Financial summary

Financial statements Chart VRCA financial data

Quarter (USD)	Sep 25	Jun 25	Mar 25	Dec 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	21.10 mm	21.10 mm	21.10 mm	21.10 mm	21.10 mm	21.10 mm
Cash burn (monthly)	(no burn)	155.17 k	(no burn)	1.37 mm	(no burn)	2.42 mm
Cash used (since last report)	n/a	362.19 k	n/a	3.19 mm	n/a	5.66 mm
Cash remaining	n/a	20.73 mm	n/a	17.91 mm	n/a	15.44 mm
Runway (months of cash)	n/a	133.6	n/a	13.1	n/a	6.4

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

VRCA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	80	81	-1.2%
Opened positions	18	20	-10.0%
Closed positions	19	14	+35.7%
Increased positions	23	24	-4.2%
Reduced positions	18	15	+20.0%

13F shares	Current	Prev Q	Change
Total value	20.81 bn	21.12 bn	-1.5%
Total shares	38.73 mm	16.38 mm	+136.5%
Total puts	5.10 k	6.50 k	-21.5%
Total calls	2.30 k	9.90 k	-76.8%
Total put/call ratio	2.2	0.7	+237.7%

Largest owners	Shares	Value	Change
Armistice Capital	8.92 mm	$6.24 bn	NEW
Paul B Manning	8.81 mm	$9.78 mm	+494.5%
Caligan Partners	7.43 mm	$5.20 bn	NEW
Perceptive Advisors	3.25 mm	$2.27 bn	-54.2%
Boothbay Fund Management	2.59 mm	$1.81 bn	NEW
Vanguard	1.88 mm	$1.32 bn	+46.1%
BlackRock	1.19 mm	$832.69 mm	+9.6%
STT State Street	523.12 k	$366.18 mm	+2.0%
Geode Capital Management	477.27 k	$334.13 mm	+4.8%
Sovran Advisors	407.05 k	$266.62 mm	NEW

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	8.92 mm	+8.92 mm	NEW
Caligan Partners	7.43 mm	+7.43 mm	NEW
Paul B Manning	8.81 mm	+7.33 mm	+494.5%
Perceptive Advisors	3.25 mm	-3.85 mm	-54.2%
Boothbay Fund Management	2.59 mm	+2.59 mm	NEW
FMR	14.67 k	-619.64 k	-97.7%
Vanguard	1.88 mm	+593.31 k	+46.1%
Sovran Advisors	407.05 k	+407.05 k	NEW
Heights Capital Management	351.14 k	+351.14 k	NEW
Propel Bio Management	0.00	-344.94 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

VRCA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
25 Nov 25	Rosenberg Noah L.	Common Stock	Buy	Acquire P	No	No	4.2425	2,357	10.00 k	2,357
25 Nov 25	Rosenberg Noah L.	Series C Warrant Common Stock	Buy	Acquire P	No	No	6.315	589	3.72 k	589
25 Nov 25	Kirby John J.	Common Stock	Buy	Acquire P	No	No	4.2425	3,536	15.00 k	8,962
25 Nov 25	Kirby John J.	Series C Warrant Common Stock	Buy	Acquire P	No	No	6.315	884	5.58 k	884
25 Nov 25	David Zawitz	Common Stock	Buy	Acquire P	No	No	4.2425	10,000	42.43 k	21,000
25 Nov 25	David Zawitz	Series C Warrant Common Stock	Buy	Acquire P	No	No	6.315	2,500	15.79 k	2,500
25 Nov 25	Jayson Rieger	Common Stock	Buy	Acquire P	No	No	4.2425	94,311	400.11 k	182,593
25 Nov 25	Jayson Rieger	Series C Warrant Common Stock	Buy	Acquire P	No	No	6.315	23,577	148.89 k	23,577
25 Nov 25	Paul B Manning	Common Stock	Buy	Acquire P	Yes	No	4.2425	2,750,762	11.67 mm	3,348,372
25 Nov 25	Paul B Manning	Common Stock	Buy	Acquire P	No	No	4.2425	1,375,380	5.84 mm	3,958,189

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Friday's Intraday Session

Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Verrica Pharmaceuticals Q3 Adj. EPS $0.13 Beats $(0.68) Estimate, Sales $14.344M Beat $5.843M Estimate

Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.68) by 119.26 percent. This is a 103.02 percent increase over losses of $(4.30) per

Verrica Pharmaceuticals To Present Phase 2 Data On VP-315 For Basal Cell Carcinoma At SITC 2025 Annual Meeting

Verrica Pharma's Development Partner, Torii Pharma, Receives Approval From Japanese MHLW For YCANTH For Treatment Of Molluscum Contagiosum

Press releases

From Benzinga Pro

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

– Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment

Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Verrica

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.